Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Income from Continuing Operations (2016 - 2025)

ImmunityBio (IBRX) has disclosed Income from Continuing Operations for 12 consecutive years, with 61958000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations fell 4.7% to 61958000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 351472000.0, a 15.03% increase, with the full-year FY2025 number at 351472000.0, up 15.03% from a year prior.
  • Income from Continuing Operations was 61958000.0 for Q4 2025 at ImmunityBio, up from 67274000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 59179000.0 in Q4 2024 to a low of 233414000.0 in Q4 2023.
  • A 5-year average of 105806850.0 and a median of 95238500.0 in 2022 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: tumbled 345.28% in 2021, then soared 74.65% in 2024.
  • ImmunityBio's Income from Continuing Operations stood at 91553000.0 in 2021, then decreased by 18.32% to 108326000.0 in 2022, then crashed by 115.47% to 233414000.0 in 2023, then skyrocketed by 74.65% to 59179000.0 in 2024, then dropped by 4.7% to 61958000.0 in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Income from Continuing Operations are 61958000.0 (Q4 2025), 67274000.0 (Q3 2025), and 92574000.0 (Q2 2025).